OncoMatch/Clinical Trials/NCT07410676
EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors
Is NCT07410676 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies EBNK-001 + IL-15 + Pembrolizumab for cancer.
Treatment: EBNK-001 + IL-15 + Pembrolizumab — This Phase 1/2 study evaluates the safety, tolerability, and preliminary anti-tumor activity of EBNK-001 (allogeneic NK cells) given after lymphodepleting cyclophosphamide/fludarabine (CY/FLU) and supported with low-dose IL-15, administered either alone or in combination with pembrolizumab in adults with advanced/metastatic solid tumors. The study will determine a recommended Phase 2 dose (RP2D) and explore signals of clinical activity using RECIST-based response criteria.
Check if I qualifyExtracted eligibility criteria
Cancer type
Sarcoma
Breast Carcinoma
Non-Small Cell Lung Carcinoma
Colorectal Cancer
Melanoma
Urothelial Carcinoma
Renal Cell Carcinoma
Pancreatic Cancer
Hepatocellular Carcinoma
Ovarian Cancer
Esophageal Carcinoma
Glioblastoma
Disease stage
Required: Stage IV
Metastatic disease required
advanced/metastatic solid tumor; Measurable disease per RECIST v1.1 (or iRECIST if applicable)
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: standard therapy
relapsed/refractory after standard therapy (or no standard therapy available)
Cannot have received: investigational agent
Receipt of investigational agent within 28 days before first study drug
Lab requirements
Blood counts
platelets ≥ 75,000/µl; hemoglobin ≥ 9 g/dl; anc ≥ 1,000/µl (unsupported by growth factors/transfusions as defined)
Kidney function
egfr ≥ 60 ml/min/1.73m²
Liver function
ast/alt ≤ 3× uln
Cardiac function
lvef ≥ 40% (by echo/muga/cmr)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify